CDK4/6 Inhibitors in Early-stage Breast Cancer
A mainstay of treatment for metastatic breast cancer, CDK4/6 inhibitors are moving into early-stage treatment.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now